|
|
| | PROSTACYCLIN SODIUM SALT Basic information |
| Product Name: | PROSTACYCLIN SODIUM SALT | | Synonyms: | Sodium (5Z,13E,15S)-6,9a-epoxy-11a,15-dihydroxyprosta-5,13-dien-1-oate;cGMP Epoprostenol (sodium salt);(5Z,13E,8R,9S,11R,12R,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oicacidsodiumsalt;Prostacyclin sodium salt Epoprostenol sodium;PGI2Na (Prostaglandin I2Na, Prostacyclin);Prostaglandin I?, Sodium Salt;EPOPROSTENOL;EPOPROSTENOL SODIUM | | CAS: | 61849-14-7 | | MF: | C20H33NaO5 | | MW: | 376.47 | | EINECS: | 263-273-7 | | Product Categories: | Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 61849-14-7.mol |  |
| | PROSTACYCLIN SODIUM SALT Chemical Properties |
| Melting point | 168-170 °C | | RTECS | UK8008700 | | storage temp. | -20°C | | solubility | H2O: 1 mg/mL Hydrolyzes to 6-ketoprostaglandin F1α in aqueous solution. | | form | powder | | color | white | | Water Solubility | Soluble to 100 mM in water | | Sensitive | Moisture Sensitive | | Merck | 13,7967 | | BRN | 6472195 | | Stability: | Light Sensitive, Temperature Sensitive | | CAS DataBase Reference | 61849-14-7(CAS DataBase Reference) |
| | PROSTACYCLIN SODIUM SALT Usage And Synthesis |
| Description | Epoprostenol is a naturally occurring prostaglandin indicated for the preservation of platelet function during cardiopulmonary bypass, prevention of platelet aggregation during charcoal hemoperfusion of patients in hepatic failure, and as an alternative to heparin during renal dialysis. | | Chemical Properties | Epoprostenol is white crystalline powder | | Originator | Burroughs Wellcome (United Kingdom) | | Uses | Prostaglandin I2 sodium salt has been used:
- in the preparation of stock solution for platelet washing procedure
- as supplement in platelet-rich-plasma, for platelet preparation
- to prevent platelet activation
| | Uses | Epoprostenol is an Eicosanoid which prevents the formation of platelet plugs and is an effective vasodilator. | | Manufacturing Process | Preparation of prostacyclin:
Pig aortas were stripped of adventitia, snap frozen in liquid nitrogen, crushed
into a fine powder, resuspended in 0.05 M Tris buffer (pH 7.5) (1:4, w:v) andhomogenised at high speed in a Polytron (KIMENATIC, LUCERNE,
SWITZERLAND) homogenizer. The homogenate was centrifuged for 15 min
and the resulting supernatant centrifuged again for 5 min. The pellet was
discarded, while the pellet obtained after centrifugation of the supernatant
was resuspended in deionized water and lyophilized. An average yield of 150
mg of aortic microsomal powder (51% protein) per 100 g of aortic tissue was
obtained. | | Brand name | Flolan (GlaxoSmithKline);CYCLO-PROSTIN. | | Therapeutic Function | Platelet aggregation inhibitor, Antimetastatic | | Biological Activity | Epoprostenol is a potent agonist at IP prostanoid receptors. Inhibits platelet aggregation and induces vasodilation. | | Biochem/physiol Actions | Prostacyclin therapy improves hemodynamics in pulmonary arterial hypertension. | | storage | Desiccate at -80°C |
| | PROSTACYCLIN SODIUM SALT Preparation Products And Raw materials |
|